SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is gaining traction amid discussions around institutional adoption and its role in digital euro and tokenized sterling initiatives with major banks. Community members highlight its limited supply and potential for interoperability, with some eyeing a breakout above $100 and targets around $500. Bullish sentiment is further fueled by exchange reserves dropping and open interest rising, aligning with the broader RWA tokenization narrative.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is trending as community members highlight its potential within the Solana ecosystem, citing its low market cap, growing holder base, and developing utility. The community is excited about upcoming announcements and the possibility of exchange listings, fueling discussions about its potential as the next big memecoin. Some users are comparing it to other successful memecoins on Solana.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

$4CHAN is trending as community members tout its potential as the 'Bitcoin of memecoins,' emphasizing its cultural relevance and unique tokenomics, including blacklisted wallets. Discussions revolve around its position as a leading memecoin and its ability to unite various internet subcultures. The community is focused on long-term holding and the potential for significant gains.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is experiencing renewed interest, with traders eyeing key breakout levels that could signal a significant rally, while others point to a potential breach of support. The community highlights recent whale activity and a possible DeFi 2.0 narrative, suggesting institutions are accumulating COMP, but revenue and concerns about the treasury runway remain in focus.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending as analysts weigh in on its AI strategy and recent customer growth, with some highlighting its potential for expansion and others citing competition. The community is watching for a breakout above the $250 resistance, while also discussing potential pullbacks and various options trading strategies. News of partnerships and integrations are also fueling interest in the stock.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending as investors digest the potential impact of the Astria Therapeutics acquisition on its long-term growth strategy and pipeline, along with upcoming data readouts. Discussions revolve around the combined company's prospects in the hereditary angioedema (HAE) market and its potential to challenge existing treatments. Some community members are expressing concern about the company's execution and capital allocation decisions, while others see significant upside potential.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending due to community excitement surrounding its pipeline, especially VEVYE, MIEBO and TRYPTYR, which are seen as potential "game changers." Investors are actively discussing the company's upcoming Q4 report and catalysts, including a pre-NDA meeting and GLP-1 platform data, with some speculating on a future $100 stock price.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending as traders assess a potential shift in market dynamics, with community members pointing to small caps potentially outperforming tech. The ETF experienced a significant intraday recovery, fueling discussions about potential rate cuts and their impact on smaller companies. Some traders are closely watching technical indicators and options flow to determine IWM's next direction amid mixed sentiment.

BYD Co., Ltd. engages in the research, development, manufacture, and sale of rechargeable batteries and photovoltaic business. It operates through the following segments: Rechargeable Batteries and Photovoltaic Products, Mobile Handset Components, Assembly Service and Other Products, and Automobiles and Related Products and Other Products. The Rechargeable Batteries and Photovoltaic Products segment is involved in the manufacture and sale of lithium-ion batteries and nickel batteries, photovoltaic products, and iron batteries products for mobile phones, electric tools, and other portable electronic instruments, photovoltaic products, energy storage products, and electric vehicles. The Mobile Handset Components, Assembly Service and Other Products segment focuses on the sale of mobile handset components such as housings, electronic components, assembly services, and medical protection products. The Automobiles and Related Products and Other Products segment consists of automobiles and auto-related moulds and components and automobile leasing and after sales services, rail transport related business, and medical protection products. The company was founded by Chuan Fu Wang on February 10, 1995 and is headquartered in Shenzhen, China.

BYD Co - Ordinary Shares - Class H

BYD Co

BYD is trending amid discussions around its global expansion, competition with Tesla, and advancements in EV technology, including a new fast-charging system. Community members are weighing the impact of potential tariffs and analyzing the company's financial performance relative to its peers. Some are closely monitoring sales data and production targets, while others discuss BYD's competitive strategies in various markets.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending following a multi-billion dollar collaboration with Bristol Myers Squibb to co-develop an experimental cancer drug, boosting investor optimism. The community is discussing the potential of BioNTech's oncology pipeline and the strategic implications of this partnership, while some remain skeptical, citing concerns about mRNA technology and potential insider activity. Overall, the focus has shifted from COVID-19 vaccines to BioNTech's broader biotech innovation and pipeline progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Abivax (NASDAQ:ABVX) Sets New 52-Week High - Still a Buy?

Abivax (NASDAQ:ABVX) Reaches New 12-Month High - What's Next...

Top Biotech Stocks To Watch Now - November 24th

argenex, Danaher, Vertex Pharmaceuticals, Abivax, Medpace, Cidara Therapeutics, and Amicus Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Top Biotech Stocks To Watch Today - November 21st

Danaher, Vertex Pharmaceuticals, Moderna, argenex, Cidara Therapeutics, Abivax, and Recursion Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...

Top Biotech Stocks To Consider - November 20th

Abivax, Cidara Therapeutics, Danaher, Vertex Pharmaceuticals, argenex, Moderna, and Cogent Biosciences are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Abivax (NASDAQ:ABVX) Sees Large Volume Increase - Here's Why

Abivax (NASDAQ:ABVX) Sees Strong Trading Volume - Here's What Happened...

Biotech Stocks To Research - November 17th

Cidara Therapeutics, Danaher, argenex, Vertex Pharmaceuticals, and Abivax are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...

Abivax (NASDAQ:ABVX) Sets New 12-Month High - Still a Buy?

Abivax (NASDAQ:ABVX) Hits New 12-Month High - Should You Buy...

Biotech Stocks To Keep An Eye On - November 16th

Cidara Therapeutics, Danaher, Vertex Pharmaceuticals, argenex, and Abivax are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of...

Biotech Stocks To Consider - November 14th

Cidara Therapeutics, Danaher, argenex, Vertex Pharmaceuticals, Abivax, Moderna, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Abivax (NASDAQ:ABVX) Sees Strong Trading Volume - Still a Buy?

Abivax (NASDAQ:ABVX) Sees Strong Trading Volume - Time to Buy...

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

ABVX
Abivax - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABVX News

ABVXAbivax - ADR